ADVANCED SCIENCE
LABORATORIES INCORPORATED
(845)-634-1500
www.advancedsl.com

50 HUMAN SUBJECT REPEAT INSULT PATCH TEST
SKIN IRRITATION/SENSITIZATION EVALUATION
(Occlusive Patch)

ADVANCED Lab No.: MS22.RIPT.A0866O.50.REDU

Date: November 28, 2022

Sponsor: Respilon Production s.r.o.
Příkop 843/4
Bmo, 602 00, Czech Republic

1.0 Objective:

Consumer products or raw materials designed for consistent reapplication to areas of the skin may, under proper conditions, prove to be contact sensitizers and/or irritants in certain individuals. It is the intention of a Repeat Insult Patch Test (RIPT) to provide a basis for evaluation of this irritation/sensitization potential if such exists.

2.0 Test Material:

2.1 Test Material Description:

On August 22, 2022 one test sample labeled RespiBeauty Rejuvenator / RB_REJ_MB015 was received from Respilon Production s.r.o and assigned ADVANCED Lab No.: A-0866.

2.2 Handling:

Upon arrival at Advanced Science Laboratories, Inc., the test material is assigned a unique laboratory code number and entered into a daily log identifying the lot number, sample description, sponsor, date received and tests requested.

Samples are retained for a period of three months beyond submission of final report unless otherwise specified by the sponsor or, if sample is known to be in support of governmental applications, representative retained samples are kept two years beyond final report submission.

Sample disposal is conducted in compliance with appropriate federal, state and local ordinances.

2.3 Test Material Evaluation Prerequisite:

Prior to induction of a human test panel, toxicology, microbiology or in-vitro performance spectra may be required to assess the feasibility of commencement as dictated by an Institutional Review Board (IRB) described in Section 3.0.

Sponsor purports that prior to sample submission the following tests were conducted with no adverse results and that the test data are on file on their premises but may not have been made available to Advanced Science personnel:

- USP or CTFA Preservative Efficacy Test or equivalent
- 90 Day Accelerated Stability and Container Compatibility Study

3.0 Institutional Review Board: [IORG 0011153][IRB00013226]

Reference: CFR Title 21 Part 56, Subparts A, B, C, and D. The IRB of Advanced Science Laboratories Inc. consists of five or more individuals, chosen from within the company for technical expertise and from the local community for lay interaction. The list of IRB members is kept on file at Advance Science Laboratories, Inc. and is available for inspection during the hours of operation.

4.0 Panel Selection:

4.1 Standards for Inclusion in a Study:

- Individuals free of any dermatological or systemic disorder which would interfere with the results, at the discretion of the Study Director.
- Individuals free of any acute or chronic disease that might interfere with or increase the risk of study participation.
- Individuals who completed a preliminary medical history form mandated by Advanced Science Laboratories, Inc. and are in general good health.
- Individuals, who read, understood and signed an informed consent document relating to the specific type of study they are subscribing. Consent forms are kept on file and are available for examination on the premises of Advanced Science Laboratories, Inc. only.
- Individuals able to cooperate with the Study Director and research staff, willing to have test materials applied according to the protocol, and complete the full course of the study.

4.2 Standards for Exclusion from a Study:

- Individuals under 18 years of age.
- Individuals who are currently taking any medication (topical or systemic) that may mask or interfere with the test results, at the discretion of the Study Director.
- Subjects with a history of any acute or chronic disease that might interfere with or increase the risk associated with study participation.
- Individuals diagnosed with chronic skin allergies.
- Female volunteers who indicate that they are pregnant or lactating.

4.3 Recruitment:

Panel selection is accomplished by advertisements in local periodicals, community bulletin boards, phone solicitation, electronic media or any combination thereof.

4.4 Informed Consent and Medical History Forms:

An informed consent was obtained from each volunteer prior to initiating the study describing reasons for the study, possible adverse effects, associated risks and potential benefits of the treatment and their limits of liability. Panelists signed and dated the informed consent document to indicate their authorization to proceed and acknowledge their understanding of the contents. Each subject was assigned a permanent identification number and completed an extensive medical history form. These forms along with the signed consent forms, are available for inspection on the premises of Advance Science Laboratories, Inc. only. Reference 21 CFR Ch. 1 Part 50, Subpart B.

The parties agreed to comply with applicable state and federal privacy laws for the use and disclosure of a subject's personal health information by taking reasonable steps to protect the confidentiality of this information. This obligation shall survive the termination or expiration of this Agreement.

5.0 Population Demographics:

Number of subjects enrolled		63
Number of subjects completing study		57
Age Range		19-77
Sex	Male	15
	Female	42
Race	Caucasian	35
	Hispanic	14
	Asian	1
	African American/Black	7

6.0 Equipment:

- Patch Description: Parke-Davis Hypoallergenic Readi Bandages or the equivalent.
- 1ml volumetric syringe without a needle.

7.0 Procedure:

- Subjects were requested to bathe or wash as usual before arrival at the facility.
- A 2cm x 2cm square of the test material was placed on the occlusive, hypoallergenic patch.
- The patch was then applied directly to the skin of the infrascapular region of the back, to the right or left of midline and the subject was dismissed with instructions not to wet or expose the test area to direct sunlight.
- After 24 hours the patch was removed by the panelist at home. If a reaction was observed the subject was required to notify ADVANCED and to present to the lab for evaluation.
- This procedure was repeated for a series of nine 24 hour induction (irritation) phase exposures.
- In the event of an adverse reaction, the area of erythema and edema was measured. Erythema or edema was estimated by evaluation of skin with respect to the contour of unaffected normal skin. Reactions were scored just before applications two through nine and the next test date following application nine. In most instances this was approximately 24 hours after patch removal. Clients were notified immediately in the case of adverse reaction and determination was made as to treatment program or discontinuation if necessary.
- Subjects were then given a 10 - 14 day rest period after which a challenge or retest dose was applied once to a previously unexposed test site. The retest dose was equivalent to any one of the original nine exposures. Reactions were scored 24 and 48 hours after application.
- Comparisons were made between the nine inductive responses and the retest (challenge) dose.
- At the conclusion of the study, the consulting Dermatologist reviewed this data and confirmed the stated conclusions.

8.0 Deviation from the protocol:

There was no deviation from protocol.

9.0 Results:

Please refer to attached Table.

10.0 Observations:

No adverse reactions to this product were noted during the course of this study.

11.0 Archiving:

All original samples, raw data sheets, technician's notebooks, correspondence files, copies of final reports and remaining specimens are maintained on the premises of Advance Science Laboratories, Inc. in limited access marked storage files for a period not to exceed two years. Sponsors are encouraged to keep all original signed, dated and certified reports. Advanced will not be responsible, and it will not be possible to provide duplicate original hard copies of final reports once the documents leave our premises.

12.0 Reference:

Appraisal of the Safety of Chemicals in Food, Drugs and Cosmetics, published by The Association of Food and Drug Officials of The United States, 1965 (modified).

13.0 Conclusions:

The test material (ADVANCED Lab. No.: A-0866; Client No.: RespiBeauty Rejuvenator / RB_REJ_MB015) when tested under occlusion as described herein, may be considered a **NON-PRIMARY IRRITANT** and **NON-PRIMARY SENSITIZER** to the skin according to the reference.

Ronda Bixon, M.D.
Clinical Laboratory Director

Yessenia Cortes, A.A.
Lead Laboratory Technician

Valeria Dubon, B.A.
Technician

Ellen Gendler, M.D.
Board Certified Dermatologist

11/30/22
Date

Advanced Science Laboratories Inc. (ADVANCED) represents testing facilities committed to the highest standards of unbiased testing and reporting. Advance Science Laboratories is not in partnership, affiliation and/or association, in any way, with any other corporation, company, sole proprietorship, partnership, client, laboratory, and/or any other business entity [collectively, Business Associate(s)]. Should any Business Associate(s) indicate via literature, advertising, reporting, publications, raw data, reports, correspondence and/or any other documentation that they are in any way in partnership, use 'partnership' language or indicate they are otherwise affiliated with ADVANCED, this shall serve as formal notice that ADVANCED shall in no event be legally bound by such claim(s) and any Business Associate(s) representing such affiliation shall, by this instrument, hold Advanced harmless and indemnify ADVANCED and from, without limitation, legal responsibility, damages, lawsuits, actions, claims, proceedings, arbitrations, and the like which may arise against ADVANCED from said Business Associate(s) claim of affiliation. Your possession of this fully executed, signed and dated, final report shall signify your acknowledgment, agreement and acceptance of and compliance with all of the foregoing.

All Services Undertaken Subject to the following General Policy: ADVANCED reports are submitted for exclusive use of the clients to whom they are addressed. Their significance is subject to the adequacy and representative character of the samples and to the comprehensiveness of the test, examination or surveys made. No quotations from Advanced reports, or use of ADVANCED names or the names of staff members or sub-contractors are permitted except as expressly authorized in writing. The liability of ADVANCED with respect to services rendered shall in no event exceed the amount of one hundred dollars. Wherein this report is used to support commercial claims, the Sponsor is directed to provide said report in its entirety only.

TABLE
SUMMARY OF RESULTS
(Occlusive Patch)

ADVANCED Lab No.: A-0866
Client No.: RespiBeauty Rejuvenator / RB_REJ_MB015

No.	Subject ID	RACE	SEX	Response 1	2	3	4	5	6	7	8	9	Chall. Patch 24HR	48HR	Score
1	10 0196	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
2	36 1138	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
3	36 1634	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
4	36 5405	C	F	0	0	0	0	0	DC	DC	DC	DC	DC	DC	DC
5	38 9585	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
6	39 0057	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
7	40 0670	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
8	40 3430	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
9	44 4149	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
10	44 8008	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
11	44 8295	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
12	46 7508	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
13	48 0738	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
14	48 2207	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
15	48 2232	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
16	50 1416	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
17	50 1810	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
18	52 5991	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
19	54 0459	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
20	54 1758	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
21	54 4489	H	M	0	0	0	0	0	0	0	0	0	0	0	0.0
22	54 6263	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
23	56 0726	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
24	56 8631	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
25	58 2655	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
26	58 3068	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
27	58 6363	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
28	58 8589	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
29	60 1936	C	F	0	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC
30	60 4697	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
31	60 5135	C	F	0	0	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC
32	60 5699	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
33	60 6310	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
34	60 9806	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
35	62 3438	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
36	62 5227	B	F	0	0	0	0	0	0	0	0	0	0	0	0.0
37	62 8757	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
38	64 4259	AA	M	0	0	0	0	0	0	0	0	0	0	0	0.0

TABLE (CONT'D)
SUMMARY OF RESULTS
(Occlusive Patch)

ADVANCED Lab No.: A-0866
Client No.: RespiBeauty Rejuvenator / RB_REJ_MB015

No.	Subject ID	RACE	SEX	Response 1	2	3	4	5	6	7	8	9	Chall. Patch 24HR	48HR	Score
39	68 0405	H	M	0	0	0	0	0	0	0	0	0	0	0	0.0
40	68 8432	H	F	0	0	0	0	DC	DC	DC	DC	DC	DC	DC	DC
41	70 3771	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
42	70 9820	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
43	72 3408	H	M	0	0	0	0	0	0	0	0	0	0	0	0.0
44	72 4989	B	M	0	0	0	0	0	0	0	0	0	0	0	0.0
45	72 9265	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
46	73 6193	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
47	74 1783	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
48	74 2987	C	M	0	0	0	0	0	0	0	0	0	0	0	0.0
49	74 5569	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
50	76 2719	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
51	76 2917	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0
52	80 6304	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
53	80 7367	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
54	86 7369	C	M	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC
55	90 0755	B	F	0	0	0	0	0	0	0	0	0	0	0	0.0
56	90 8772	H	M	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC	DC
57	94 3048	B	F	0	0	0	0	0	0	0	0	0	0	0	0.0
58	94 5644	B	F	0	0	0	0	0	0	0	0	0	0	0	0.0
59	94 6069	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
60	98 0287	B	F	0	0	0	0	0	0	0	0	0	0	0	0.0
61	98 1792	A	F	0	0	0	0	0	0	0	0	0	0	0	0.0
62	98 8131	H	F	0	0	0	0	0	0	0	0	0	0	0	0.0
63	99 6974	C	F	0	0	0	0	0	0	0	0	0	0	0	0.0

Evaluation Period: This study was conducted from October 17, 2022 through November 18, 2022.

Scoring Scale and Definition of Symbols Shown in Table:

0.0	-	No evidence of any effect
0.5	-	(Barely perceptible) minimal faint (light pink) uniform or spotty erythema
1.0	-	(Mild) pink uniform erythema covering most of contact site
2.0	-	(Moderate) pink\red erythema visibly uniform in entire contact area
3.0	-	(Marked) bright red erythema with accompanying edema, petechiae or papules
4.0	-	(Severe) deep red erythema with vesiculation or weeping with or without edema
DC	-	Subject discontinued, unrelated to sample
S	-	Skin stained from pigment in product, unable to grade reaction
T	-	Tan, unable to grade reaction
ad	-	adjacent patch
[ ]^{E}	-	image of the patch site was electronically transmitted
M	-	Mixed Heritage
AA	-	African American
A	-	Asian
H	-	Hispanic
B	-	Black
C	-	Caucasian

NOTE: All technical employees of Advance Science Laboratories Inc. are required to take and pass a visual discrimination examination overseen by a Board Certified Ophthalmologist using the Farnsworth-Munsell 100 Hue Test as published; which determines a person's ability to discern color against a black background. This test was additionally modified to include a flesh tone background more nearly approaching actual use conditions, wherein erythematous skin is graded according to intensity.

14.0 Quality Assurance Statement:

This study was inspected in accordance with the Standard Operating Procedures of Advance Science Laboratories. To assure compliance with the study protocol, the Quality Assurance Unit completed an audit of the study records and report.

Report reviewed by:

Jennifer Conforto, M.A.
Quality Assurance Supervisor

12/2/22
Date